<DOC>
	<DOCNO>NCT01348243</DOCNO>
	<brief_summary>Clodronic acid 100 mg/3,3 ml use prevent treat postmenopausal osteoporosis . The intramuscular formulation , give dose 100 mg every 7 14 day , least effective daily oral therapy appear effective intermittent intravenous treatment . Intramuscular clodronic acid particular also associate improvement back pain . The drug well tolerate , deleterious effect bone mineralization , use parenteral therapy eliminate risk gastrointestinal adverse effect may see patient receive oral bisphosphonates therapy . In order simplify therapeutic dose regimen , reduce number administration per month , therefore increase adherence bisphosphonates therapy patient , new formulation disodium clodronic acid contain 200 mg/4 mL i.m . administration develop . Lidocaine new formulation , local anaesthetic , maintain concentration 100 mg clodronic acid formulation . The pharmacokinetics tolerability intramuscular formulation clodronic acid 200 mg comparison market formulation clodronic acid 100 mg evaluate healthy post-menopausal volunteer . Two formulation similar term amount rate clodronic acid urinary excretion term safety profile .</brief_summary>
	<brief_title>Efficacy Of Clodronate 200 Mg/4 Ml I.M . Solution With 1 % Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M . Solution With 1 % Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Clodronic Acid</mesh_term>
	<criteria>1 . Subject 's write informed consent obtain prior studyrelated procedure ; 2 . Postmenopausal ( menses last 5 year ) female subject &gt; 50 year old lumbar femoralneck Tscore &lt; 2,5 &gt; 4 ; 3 . At least three intact vertebra L1 L4 ; 4 . Patients treat accord nonpharmacological standard care ; 5 . Patients possibility willingness take i.m . injection . 1 . BMI &lt; 19 kg/m2 ; 2 . History : use intravenous bisphosphonates , 12 month bisphosphonates continuative strontium ranelate use ever , use bisphosphonates ( oral injective ) within last year , rhPTH use ( recombinant human PTH ) last 2 year , calcitonin use within past 3 month , raloxifene tamoxifen last 6 month 12 month last 2 year , fluoride ( &gt; 1 mg/die ) least month within past 5 year ; 3 . Use estrogen ( oral patch ) 1 month last 6 month 12 month last 2 year ; 4 . Serious disease oral cavity surgery and/or dental implant less month plan next 12 month ; 5 . Type 1 uncontrolled type 2 diabetes mellitus ( define hemoglobin A1C &gt; 10,0 ) , currently use insulin ; 6 . Family history malignant hyperthermia ; 7 . Heart disease , particularly bradyarrhythmias heart failure ; AdamsStokes syndrome , WolffParkinsonWhite syndrome severe degree sinoatrial , atrioventricular intraventricular block , acute cardiac decompensation ; 8 . History kidney failure renal insufficiency ( serum creatinine &gt; 2,0 mg/dl ) ; 9 . History stroke last 6 month uncontrolled hypertension ; 10 . Any history hypercalciuria ; 11 . History hypercalcemia , sarcoidosis , hyperparathyroidism , hypothyroidism hyperthyroidism ; 12 . History malignancy except epithelioma consider cure ; 13 . Patients currently treat systemic prednisone equivalent per day &gt; 2000 mcg beclomethasone dipropionate equivalent daily ; ; 14 . Patients currently treat antiepileptic drug , anticoagulant anticonvulsant treat last 6 month 12 month last 2 year ; 15 . Patients current treated propanolol , cimetidine digitalis drug ; 16 . History alcohol drug abuse ; 17 . Allergy , sensitivity intolerance study drug ( include lidocaine amidetype local anaesthetic ) excipients ; 18 . Subjects unlikely comply study protocol unable understand nature scope study also possible benefit unwanted effect study treatment ; 19 . Subjects receive investigational new drug , participate clinical study within last 12 week ; 20 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>